About Heterogeneous nuclear ribonucleoprotein A3
Heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) is a protein
from Homo sapiens identified by UniProt accession
P51991, 378 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoprotein A3 |
|---|
| UniProt accession | P51991 |
|---|
| Gene | HNRNPA3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 378 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (59)
Diseases linked to this target (Open Targets).
- pulse pressure measurement · score 0.36
- sex hormone-binding globulin measurement · score 0.26
- balding measurement · score 0.25
- hair shape measurement · score 0.24
- PHF-tau measurement · score 0.24
- hemoglobin measurement · score 0.21
- hematocrit · score 0.20
- alopecia · score 0.17
- androgenetic alopecia · score 0.17
- red blood cell density measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P51991-F1 | alphafold | PREDICTED | 66.49 | — |
Amino-acid sequence (378 residues)
MEVKPPPGRP QPDSGRRRRR RGEEGHDPKE PEQLRKLFIG GLSFETTDDS LREHFEKWGT LTDCVVMRDP QTKRSRGFGF VTYSCVEEVD AAMCARPHKV DGRVVEPKRA VSREDSVKPG AHLTVKKIFV GGIKEDTEEY NLRDYFEKYG KIETIEVMED RQSGKKRGFA FVTFDDHDTV DKIVVQKYHT INGHNCEVKK ALSKQEMQSA GSQRGRGGGS GNFMGRGGNF GGGGGNFGRG GNFGGRGGYG GGGGGSRGSY GGGDGGYNGF GGDGGNYGGG PGYSSRGGYG GGGPGYGNQG GGYGGGGGYD GYNEGGNFGG GNYGGGGNYN DFGNYSGQQQ SNYGPMKGGS FGGRSSGSPY GGGYGSGGGS GGYGSRRF
Explore Heterogeneous nuclear ribonucleoprotein A3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets